179 results
8-K/A
EX-10.2
CHRS
Coherus Biosciences Inc
21 May 24
Financial Statements and Exhibits
5:14pm
collected by it or on its behalf from and against unauthorized access, use and/or disclosure. The Seller has, to the Seller’s Knowledge, been … of security of unauthorized access by third parties of any Personal Information in its possession, custody, or control that might reasonably be expected
8-K/A
EX-10.1
CHRS
Coherus Biosciences Inc
21 May 24
Financial Statements and Exhibits
5:14pm
Property Rights
Books and Records
Access to Collateral; Audits
Use of Proceeds
Further Assurances
Additional Collateral; Guarantors
Formation … , executed by Borrower and the Collateral Documents (but excluding any Control Agreements, Collateral Access Agreements and any other Loan Document
8-K
EX-99.1
CHRS
Coherus Biosciences Inc
9 May 24
Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
4:17pm
, starting at 5:00 p.m. Eastern Daylight Time
To access the conference call:
Dial: (800) 715-9871 (toll-free USA and Canada); (646) 307-1963 (international
8-K
EX-99.1
gr6zl
13 Mar 24
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
4:16pm
8-K
EX-99.1
lswnq32e3y2 b9
4 Mar 24
Completion of Acquisition or Disposition of Assets
6:22am
8-K
EX-99.2
hm47af7mo0wi2ih4ekq6
4 Mar 24
Completion of Acquisition or Disposition of Assets
6:22am
8-K
EX-10.1
stk7vfcb5cys 9jo
5 Feb 24
Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP
8:09am
8-K
EX-99.1
btlxp b2ohkduwl
22 Jan 24
Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in Conference Call Information
8:01am
8-K
EX-2.1
r6fo9fsp
22 Jan 24
Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in Conference Call Information
8:01am
8-K
EX-99.1
0v8t6fe63 misi
6 Nov 23
Coherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights
4:31pm